UBS Group’s Aehr Test Systems AEHR Stock Holding History

UBS Group’s Portfolio AEHR Stock Details AEHR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.87M	Buy	+29,900	New	+$2.73M	﹤0.01%	4759
2024 Q1	–	Sell	-48,600	Closed	-$1.29M	–	9236
2023 Q4	$1.29M	Buy	+48,600	New	+$1.42M	﹤0.01%	4263

Other funds holding AEHR

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

UBS Group's AEHR Position: Q2 2026 in Review

UBS Group reduced its Aehr Test Systems (AEHR) stake by 31% in Q2 2026, selling an estimated $7.09M and leaving 169,123 shares worth $16.2M. The position accounts for ﹤0.01% of the portfolio, ranked #2905.

UBS Group first reported a position in AEHR in Q4 2014 and has held it in 31 quarters since. 262 funds tracked by Wall St. Rank hold AEHR as of Q2 2026.

UBS Group held 169,123 shares of Aehr Test Systems worth $16.2M as of Q2 2026.
UBS Group sold 77,640 Aehr Test Systems shares in Q2 2026, an estimated $7.09M.
Aehr Test Systems made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #2905 holding.
UBS Group first reported a position in Aehr Test Systems in Q4 2014 and has held it in 31 quarters since.
262 funds tracked by Wall St. Rank held Aehr Test Systems as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.